Quest Diagnostics (DGX) DIvidends Date & History

Key Takeaways

• Consistent payer: DGX distributes a quarterly dividend currently set at $0.86 per share, or $3.44 per share on an annualized basis.
• Modest yield: The dividend yield sits around 1.5%, lower than many income-oriented peers but supported by a reliable, growing payout.
• Growth track record: Quest Diagnostics has increased its dividend for more than a decade of consecutive years, with roughly 7% average annual growth over the past five years.
• Healthy coverage: The payout ratio of roughly 35% of earnings and about 23% of free cash flow leaves ample room for future increases.
• Latest raise: The company boosted its quarterly dividend by 7.5% in early 2026, from $0.80 to $0.86 per share.

Dividend Overview

Quest Diagnostics (DGX), a leading provider of diagnostic information services, pays a regular quarterly dividend of $0.86 per share, translating to an annualized payout of $3.44 per share. Based on recent trading levels, this equates to a dividend yield of approximately 1.5%, which is modest relative to high-yield categories but consistent with the company's focus on steady, compounding growth.

Quest Diagnostics is best characterized as a dividend growth stock rather than a high-yield play. Its dividend is reliable, paid every three months, and has been raised annually for well over a decade. The company's most recent increase—a 7.5% lift announced in early 2026—reflects management's confidence in durable cash generation and a disciplined approach to returning capital to shareholders alongside its share repurchase program.

Dividend History and Growth

Quest Diagnostics has built a consistent record of returning cash to investors, increasing its quarterly dividend for more than a decade in a row. The payout has climbed from $0.53 per share in early 2020 to $0.86 per share today, with the company raising its dividend by 7.5% in early 2026 from $0.80 to $0.86 per share.

Over the past five years, the dividend has grown at an average annualized rate of roughly 7%, outpacing inflation and underscoring a commitment to steadily increasing shareholder payouts. The company has avoided cuts during this period, reflecting the resilience of its diagnostic testing business across economic cycles. This long-term strategy—modest but dependable increases—positions DGX as a candidate for investors who value predictability and gradual income growth over time.

Dividend Sustainability and Payout Ratio

Quest Diagnostics' dividend appears well-covered and sustainable. The company's payout ratio stands at approximately 35% of trailing earnings, and it distributes only about 23% of its free cash flow as dividends. These figures are comfortably below thresholds that would raise concern, leaving meaningful capacity to fund operations, invest in growth, and continue raising the dividend.

The low payout ratio also provides a cushion against earnings variability, meaning the dividend is unlikely to be jeopardized by a temporary dip in profitability. Combined with the firm's stable, recurring revenue base in laboratory testing and diagnostic services, Quest Diagnostics maintains the financial flexibility to support both its dividend and strategic investments. This conservative approach signals that the payout is not only sustainable but has room to keep growing.

Dividend Compared to Industry Peers

Within the healthcare and diagnostics sector, Quest Diagnostics' dividend yield of roughly 1.5% sits below the broader healthcare industry median of about 2.1%, reflecting the stock's higher valuation and growth orientation. Its closest large-cap peer, Labcorp (LH), offers a similarly modest yield, reinforcing that diagnostic-services companies typically prioritize dividend growth and share repurchases over maximizing current income.

What DGX may lack in headline yield, it compensates for with a long streak of annual increases and a conservative payout ratio. For investors weighing yield against reliability, Quest Diagnostics presents a lower-yielding but steadier alternative to high-payout healthcare names that may carry greater earnings volatility or slower dividend growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual screening. Explore the AI Screener to streamline your search for income and growth opportunities.

Is This Stock Attractive for Dividend Investors?

Quest Diagnostics is likely to appeal primarily to dividend growth investors and long-term, conservative investors who prioritize reliability and compounding income over maximizing current yield. Its roughly 1.5% yield is modest, so investors seeking immediate, high cash income may find better options elsewhere in the market.

However, for investors focused on a steadily rising payout, DGX offers a compelling profile: a decade-plus streak of annual increases, an average growth rate near 7% over five years, and a low payout ratio that leaves substantial room for future hikes. The company's defensive, recurring-revenue business model in diagnostic testing also supports dividend stability across economic cycles. While the stock may not suit pure income seekers, it fits well within a diversified, long-horizon portfolio oriented toward growing, dependable dividends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations